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ABSTRACT 
KDM4 proteins are epigenetic modifiers that demethylate histone lysine residues to regulate 
chromatin structure and gene expression. The KDM4 subfamily contributes to the larger JmjC 
domain containing demethylase family, which all require 2-ketoglutarate as a cofactor for 
catalytic activity. KDM4 members have been shown to be relevant in biological processes, such 
as cellular differentiation and DNA damage repair. The amplification of KDM4 proteins has 
been observed in various cancers and disrupts the cell cycle, normal cellular proliferation and 
apoptosis. Being able to monitor the members of this protein family independently will elucidate 
their specific functions and the genes they regulate. Because this family of proteins is involved in 
various mechanisms related to pathogenesis it is of significant public health importance.  
The Bump-Hole approach was used to develop an engineered KDM4A-2-Ketoglutarate 
system that would be independent of the native demethylase system. In total, 24 KDM4A 
mutants and 12 2-ketoglutarate analogs were generated, providing 288 engineered systems to be 
screened for activity. Half of the KDM4A mutants showed activity with 2-KG compounds and 
three of them provided a bioorthologous enzyme-cofactor system.  The most significant 
engineered KDM4A-2-KG pairs were tested in KDM4 isoforms B and D and gave similar 
Kabirul Islam, PhD 
ALLELE SPECIFIC APPROACH TO STUDY HISTONE DEMETHYLATION 
USING ENGINEERED KDM4A- (2) KETOGLUTARATE PAIRS 
Megan Marie Breski, M.S. 
University of Pittsburgh, 2015
v 
results. Engineering the enzyme did not disrupt substrate specificity and the engineered systems 
were active following methylation of histone peptides.  
In conclusion, half of the KDM4A mutants rendered the enzyme inactive when paired 
with the 2-KG compounds obtained (including the native compound). Half of the KDM4A 
mutants showed activity with at least one of the 2-KG compounds, where three of them resulted 
in a bioorthologous enzyme-cofactor system. The observations were alike in the KDM4 isoforms 
and substrate specificity was maintained. These results allow for the KDM4A protein to be 
monitored independently of the KDM4 isoforms and other JmjC domain containing proteins.  
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1.0  BACKGROUND AND SIGNIFICANCE 
1.1 INTRODUCTION TO EPIGENETICS 
Epigenetics is the study of gene regulation, chromatin organization and phenotypic changes that 
do not involve changes in the DNA sequence. The human genome is compacted into the 
structure of chromatin and epigenetic mechanisms regulate the transition between euchromatin 
(de-condensed chromatin that permits access of transcriptional machinery to DNA) and 
heterochromatin (tightly condensed chromatin keeping transcriptional machinery from accessing 
DNA). Nucleosomes are the principal components of chromatin and they consist of 146-147 bp 
of DNA wrapped around a histone octamer core. The octamer core includes two copies of the 
histones H2A, H2B, H3 and H4 (Figure 1). Linker DNA and histone H1 compact the core further 
to become a 30nm fiber [1-2].  
Epigenetic post-translational modifications (PTMs) are temporary covalent chemical 
changes such as acetylation, methylation and phosphorylation etc. with DNA, RNA or histones 
as substrates. The general mechanism for PTMs to occur is the addition of the modification to 
the substrate (‘writing’), the processing and recognition of the modification (‘reading’) and the 
removal of the modification from the substrate (‘erasing’). This cycle of ‘writing’, ‘reading’ and 
‘erasing’ requires various families of proteins and differs mechanistically depending on the 
substrate and modification [3-4].  
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Figure 1: Nucleosome Core Crystal Structure 
An image showing the DNA double helix, histone octamer core and a histone tail exposed to 
post translational modifications such as methylation and demethylation. The image was taken 
from SciencePhoto.com  
 
The biological impact of PTMs is being explored, but is convoluted by the vast array of 
protein families involved in the diverse mechanisms. Hundreds of proteins have been identified 
to contribute to the dynamic process of PTMs and there is evidence that these proteins are 
implicated in diverse biological processes such as development, differentiation, imprinting and 
homeostasis. Several of the enzymes involved in epigenetic mechanisms have altered expression 
in various pathologies and disorders. For instance, KDM4 proteins (histone demethylases) are 
overexpressed in many types of cancers and FTO (RNA demethylase) is associated with obesity. 
DNA double helix 
Octomer Core 
Histone Tail 
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Because of necessity of these enzymes in the regulation of biological pathways and the 
implications of them in various diseases and public health in general, the understanding of their 
function and interactions can elucidate therapeutic targets.  
1.2 SUBSTRATES OF POST TRANSLATIONAL MODIFICATIONS 
PTMs occur on DNA, RNA and proteins and are regulated by specific enzymes for proper cell 
functioning. The various families of enzymes that are involved in PTMs have different 
mechanisms and levels of expression, but may have similar cofactors. A brief overview of PTMs 
on DNA and RNA will be discussed, but the focus will be on histone methylation. 
 DNA methylation mainly occurs at CpG islands where cytosine bases are converted to 5-
methylcytosine (5mC) by DNA methyltransferases (DNMTs) and is associated with gene 
repression. DNMTs either act as de novo DNMTs, which bind unmethylated DNA and generate 
the initial methylation pattern or act as maintenance DNMTs, which use an existing DNA strand 
as a template to copy the methylation pattern after DNA replication occurs. Promoters and 
regulatory components are the most common region of the genome that becomes methylated, 
which may be due to a protective mechanism. About 70% of the promoters in the human genome 
are considered CpG island promoters, but in most cell types they are active and unmethylated. 
Transcription factors and other proteins with certain domains (e.g. CXXC zinc finger domain) 
bind unmethylated CpGs to keep regions from becoming methylated which can act as protection 
for promoters or as regulation for other regions of the genome. DNA demethylation can be 
characterized as either passive or active. Passive demethylation is replication dependent where 
newly synthesized DNA does not have the methylation pattern because PTMs are not replicated. 
 4 
Active demethylation is replication-independent and is seen throughout different cell types and 
loci. The process of removing the methyl groups from cytosine nucleotides continues to be 
explored and is not fully understood. Methylated DNA binding domain-containing protein 
MBD2 and human ten-eleven-translocation (TET) proteins have been shown to act as a methyl 
‘erasers’ on DNA by converting 5mC to 5-hemimethylcytosine (5hmC) requiring 2-ketoglutarate 
as a cofactor [5-7].  
The stages of the DNA methylation process can be easily depicted through imprinting 
mechanisms. DNA methylation patterns are lost when fertilization occurs to regain the 
pluripotency status, but the imprinting-related DNA methylation is re-established in primordial 
germ cell stage. The 5mC maternal genome is lost after fertilization via passive demethylation 
whereas the 5mC paternal genome is lost in a matter of hours suggesting a globally active 
demethylation pathway. The DNA methylation pathway is essential for development, 
differentiation and regulation of gene expression as well as maintaining cellular identity. 
Methylation patterns and the activity of the proteins involved in DNA methylation are tissue and 
developmental stage specific [8]. 
Modifications in coding and non-coding RNA have been reported, but the function of the 
various modifications has yet to be elucidated. N6-methyladenosine (m6A) characterizes 0.1-
0.4% total adenosine residues in the transcriptome and is found in mRNA, snRNA, tRNA and 
rRNA. In mRNA, there is approxiamately 1 m6A every 2000 ribonucleotides and is sequence 
specific, although the consensus sequence for the m6A modification varies depending on the type 
of RNA substrate. It is predominantly found in mature mRNA in coding sequences and near stop 
codons in the 3’UTRs, but not on the poly(A) tails. This modification is not randomly dispersed 
throughout the mRNA transcript, but it is commonly found in adjacent regions supporting the 
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idea that there is functional significance. There is also evidence suggesting that highly expressed 
microRNAs (miRNAs) may regulate methylation of their targets because they target transcripts 
with m6A in the 3’UTR [8]. MicroRNAs (miRNAs) have also been shown to have methylation 
modifications that prevent miRNA maturation. The modifications on mRNA result in different 
phenotypes depending on the specific modification site. The m6A mark at one site may lead to 
the recruitment of m6A binding proteins to induce mRNA processing, mRNA trafficking or 
translation, but the modification at a different site could prevent the accessibility of RNA binding 
proteins for translating and this could explain the inverse correlation between mRNA copy 
number and protein abundance/expression [9]. 
Multi-protein complexes that harbor methyltransferase like 3 (METTL3), SAM (S-
adenosylmethionine-binding domain), accomplish methylation of RNA. METTL3 has two 
functional domains, consensus methylation motif I (CM I) and consensus methylation motif II 
(CM II) which are the SAM binding domain and the catalytic domain respectively. FTO and 
ALKBH5 are known RNA demethylases and belong to the AlkB family. Characteristics of the 
AlkB family are the iron binding motif and the 2-KG interaction domain. The m6A modification 
is known to regulate meiosis, metabolism and transcription making it an important biological 
mechanism [9].   
The N-terminal histone tails extend from the nucleosomal core allowing for post-
translational modifications (PTMs) to occur. With histones being an integral part of chromatin it 
is important to understand how they are being modified epigenetically and what it results it 
phenotypically [3-4].   
Protein methyltransferases (PMTs) transfer methyl groups on to and off of various 
proteins and make up >50% of the chromatin-modifying enzymes in humans. The main class of 
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PMTs includes two families: protein lysine methyltransferases (PKMTs) and protein arginine 
methyltransferases (PRMTs) [10].  
PMT activity on histone lysine residues can result in varying degrees of chemical states: 
mono-, di-, or tri- methylation and they correspond to unique phenotypic effects within the cells. 
For example, the phenotypic outcome correlated with trimethylation of H3K9 is a constitutively 
condensed heterochromatin state and trimethylation of H3K27 is a euchromatin state with gene 
silencing. PMTs catalyze the reaction of a methyl group transfer from SAM, the universal methyl 
donor, to the nitrogen acceptor of amino acids, predominantly lysine or arginine. Recognition of 
methylation states can be performed by PMTs that contain ‘reader’ domains, which can 
subsequently trigger downstream processes. There is a considerable amount of structural 
diversity within the substrate-binding pocket and substrate specificity among PMTs, which 
promotes the development of inhibitors to target individual PMTs specifically [10-11].  
Methyltransferase G9a transfers methyl groups from SAM onto histone 3 (H3) lysine 9 
(K9) and H3K27 through its SET (Su (var), enhancer of zeste, trithorax domain) domain. 
Specific amino acid residues within the histone substrates are essential for G9a activity. For 
instance, the arginine (R) at position 8 on histone 3 is adjacent to the lysine residue that is 
methylated by G9a and substituting it for any other amino acid completely abolishes the 
methylation of H3K9 by G9a. This shows that methyltransferases have site specificity for a 
specific sequence motif similar to DNMT and METTL3. G9a activity is also impaired by the 
phosphorylation of amino acid residues near H3K9. The motif recognized by G9a is found in 
several non-histone proteins and can be methylated. In fact, G9a is automethylated at its N-
terminus resembling tri-methylated H3K9 (H3K9me3). Other non-histone protein substrates for 
G9a include DNMT1, HDAC1 (Histone deacetylase 1), p53 and Reptin. The phenotypic impact 
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of methylation on non-histone proteins has not been understood for all cases, but has been 
unmasked for some. For instance, at specific lysine sites reptin methylation induces a mechanism 
to cope with hypoxia and methylated p53 causes the protein to be transcriptionally inactive. 
Depletion or overexpression of G9a results in dysregulated differentiation of various cell types 
affecting brain, skeletal muscle and adipocyte development etc. and is observed in many 
different types of cancers [12-13].  
Methylation of histones plays a role in diverse biological mechanisms. Histone 
methylation can regulate gene expression by antagonizing the effects that other histone 
modifications (e.g. histone acetylation) have on gene expression through the binding of 
chromodomains [14].  
Histone demethylases remove methyl groups in a site and state specific manner. Many 
histone demethylases harbor ‘reader’ domains, such as the Tudor domain, to recognize the 
modifications and act as effector proteins. Histone demethylation is an important biological 
phenomenon and will be the focus of the document and expanded upon in the upcoming chapters 
[4]. 
Epigenetic modification patterns vary depending on developmental stage, cell type and 
tissue type. Several proteins are involved in the dynamic processes that regulate the addition and 
removal of the covalent epigenetic modifications and these proteins interact with each other and 
influence downstream pathways such as transcription, replication, and expression on the gene 
and protein level. For each substrate there are specific chemical mechanisms to explain how 
these modifications occur and why they occur where they do, but they are not fully understood. 
Many of the proteins involved have structural similarities with some specific differences and this 
allows for co-factors required for activity to be redundantly used to interact with catalytic 
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domains and for site specific modification. For example, 2-KG is a co-factor that can be used by 
several families of methyltransferases and demethylases [10-13].  
1.3 DYNAMICS OF HISTONE METHYLATION AND DEMETHYLATION 
Several histone modifications collectively regulate and play a role various biological processes 
such as transcription, DNA replication and DNA repair. Understanding the effects of specific 
histone methylation modifications on chromatin regulation and function has become possible 
with the characterization of various histone methyltransferases. As the comprehension of histone 
methylation expands, generalizing the correlation of specific histone marks with certain 
phenotypic outcomes (e.g. transcriptional silencing vs. transcriptional activation) becomes more 
complex. Generally, H3K9 and H3K27 methylation is correlated with transcriptional silencing, 
but both have been observed in some regions of transcriptionally active chromatin. Also, 
methylation of H3K4 and H3K36 are associated with transcriptional activation, but can be seen 
in chromatin regions of transcriptional silencing.  As stated earlier, there are various methylation 
states that histone residues undertake: mono- (me1), di- (me2) and tri- (me3) and are most 
abundant on histone H3 and H4 lysine or arginine residues. Methylated lysine residues have also 
been observed on linker histone H1. These modification states dictate which effector proteins 
recognize the modification and vary throughout development, tissue type and pathologies. Table 
1 shows a comprehensive list of general associations between histone methylation marks and 
biological function. Methylation modification state can increase (via methyltransferases activity) 
and decrease (via demethylase activity) providing a dynamic chemical process essential for 
various biological pathways [15].  
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Table 1. Methylation State Functions of Histone Lysine Residues 
 
Three classes of enzymes that remove histone methylation have been characterized: 
peptidylarginine deiminases (PAD), flavin-dependent lysine specific demethylases (LSD) and 
JmjC domain containing demethylases (JMJ). Each class requires specific cofactors and target 
residues in a site and state specific manner [15].  
The PAD family targets methylated arginine residues on histone 3 and histone 4. They 
are not necessarily considered histone demethylases because they convert methylated histone 
arginine to citrulline (citrullination) rather than reversing arginine methylation directly. PADs 
require calcium and dithiothreitol (DTT) to perform citrullination where the arginine side chain 
Methylation Site Methylation State Associated Functions
me1 transcriptional activation in enhancer regions
me2 Gene activation in promoter regions
me3 Gene activation in promoter regions
me1 Gene activation [18]
me2 Transcriptional repression  [18]
me3 Transcriptional repression  [18]
me1 Gene activation [18]
me2 Transcriptional repression
me3 Transcriptional repression  [18]
me1 Gene activation [19]
me2 Gene activation [25]
me3 Transcriptional repression  [18-19]
me1
Gene activation, DNA replication, DNA repair, Mitotic 
Regulation  [18]
me2 Gene activation, DNA replication, DNA repair [19]
me3 Transcriptional repression  [18-19]
me1 Gene activation
me2 Gene activation
me3 transcriptional repression; heterochromatin formation [19]
H3K79
H4K20
H1.4K26
H3K4
H3K9
H3K27
H3K36 me1, me2, me3 Transcriptional elongation, association with RNA Pol (II) 
and histone deacetylation (18,24)
10 
guanidine group is converted to a ureido group. There are five isoforms in the PAD family 
(PAD1-4 and PAD6) and they each have tissue specific expression patterns. PADs are involved 
in myelin formation and hair growth and have been implicated in various pathologies such as 
cancer, rheumatoid arthritis, Alzheimer’s and multiple sclerosis [16-17] 
The discovery of the first lysine demethylase (KDM), termed Lysine Specific 
Demethylase 1 (LSD1) in 2004 eliminated the idea that lysine methylation is irreversible. LSD1 
catalyzes the removal of methyl groups from H3K4me1 and H3K4me2 as well as some non-
histone proteins. LSD1 is a flavin dependent amine oxidase and consists of an amine oxidase 
catalytic domain, an N-terminal SWIRM domain involved in recognition of the specific target 
and an N-terminal extension. LSD1 can be thought of as an inducer of transcriptional silencing 
because it specifically targets H3K4me1/2, which is known to be associated with transcriptional 
activation, and has been shown to be involved in protein-protein interactions with transcriptional 
repressive complexes (e.g. CoREST and HDAC1/2) [23]. 
1.4 JMJC DOMAIN CONTAINING DEMETHYLASES 
The human genome encodes 32 JmjC-domain containing genes with 24 of them showing 
demethylase activity. There are various combinations of domains (e.g. PHD, Tudor, ARID, 
JmjN) incorporated in JmjC-domain containing proteins, which define their function.  The 24 
JmjC domain containing demethylases are categorized into seven subfamilies based on structure 
and sequence homology and each target specific methylated lysine residues based on sequence 
and methylation state. A comprehensive list is shown in Table 2 [26-27].   
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There are five functional KDM4 genes: KDM4A-E, which are localized to various 
chromosomes. Interestingly, KDM4D is an intronless gene that clusters with KDM4E and 
KDM4F. KDM4F is considered a pseudogene as was KDM4E, but it was recently suggested that 
it is a functional gene by evidence for its expression. Orthologs of KDM4A-C are seen in all 
vertebrates whereas orthologs of KDM4D are seen only in placental mammals providing support 
that the five membered KDM4 subfamily is highly conserved [26-28]. 
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Table 2. Human demethylase chromosomal location, protein structure and histone substrates. 
 
SWIRM domain: pink; Amine oxidase domain: dark green; CW-wild type zinc-finger domain: light pink; 
JmjC domain: light green; CXXC zinc-finger domain: orange; PHD plant homeodomain: purple; F-box 
domain (FBOX): white; Leu-rich repeat domain (LRR): brown; JmjN domain: red; Tudor domain: 
yellow; AT-rich interacting domain (ARID): Blue; C5HC2 zinc-finger domain: grey; Tetratricopeptide 
domain (TPR): aqua.  
Demethylase Synonyms Gene.loci Domains Histone.Targets
KDM1A LSD1,)KDM1,)AOF2,)
BHC110
1p36.12 H3K4me1/me2,)H3K9me1/me2
KDM1B LSD2,)AOF1,)C6orf193 6p22.3 H3K4me1/me2
KDM2A JHDM1A,)FBXL11,)CXXC8,)
FBL11,)FBL7
11q13.2 H3K36me1/me2
KDM2B JHDM1B,)FBXL10,)PCCX2)
CXXC2
12q24.31 H3K4me3,)H3K36me1/me2
KDM3A JHDM2A,)JMJD1A,)TSGA 2p11.2 H3K9me1/me2
KDM3B JMJD1B,)NET22 5q31 H3K9me1/me2
KDM3C KDM3C,)TRIP8 10q21.3 H3K9me1/me2
KDM4A JMJD2A,)JHDM3A,)JMJD2 1p34.1 H3K9me2/me3,)H3K36me2/me3,)
H1.4K26/me2/me3
KDM4B JMJD2B 19p13.3 H3K9me2/me3,)H3K36me2/me3,)
H1.4K26/me2/me3
KDM4C JMJD2C,)JHDM3C,)GASC1 9p24.2 H3K9me2/me3,)H3K36me2/me3,)
H1.4K26/me2/me3
KDM4D JMJD2D 11q21 H3K9me2/3,)H1.4K26me2/me3
KDM4E JMJD2E,)KDM4DL 11q21 H3K9me2/me3,)H3K56me3
KDM5A JARID1A,)RBP2 12p11 H3K4me2/me3
KDM5B JARID1B,)CT31,)RBBP2H1A 1q32.1 H3K4me2/me3
KDM5C JARID1C,)SMCX,)MRXJ Xp11.22 H3K4me2/me3
KDM5D JARID1D,)HY,)SMCY Yq11 H3K4me2/me3
KDM6A UTX,)KABUK2 Xp11.2 H3K27me2/me3
KDM6B JMJD3 17p13.1 H3K27me2/me3
KDM7A JHDM1D 7q34 H3K9me1/me2,)H3K27me1/me2
KDM7B PHF8,)JHDM1F,)MRXSSD,)
ZNF422
Xp11.22 H3K9me1/me2,)H4K20me1
KDM7C PHF2,)JHDM1E,)CRC5 9q22.31 H3K9me2
MINA MDIG,)FLJ14393 3q11.2 H3K9me3
NO66 MAPJD 14q24.3 H3K4me1/me3,)H3K36me2
KDM8 JMJD5 16p12.1 H3K36me2
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1.5  KDM4 PROTEIN MEMBER STRUCTURE AND SPECIFICITY 
KDM4A-C are the larger proteins within this subfamily and share greater than 50% sequence 
identity. The domains within each member play essential roles for correct protein function. 
KDM4A-C isoforms contain N-terminal JmjN and JmjC domains and on the C-terminal contain 
two PHD and two Tudor domains. KDM4D and KDM4E lack the PHD and Tudor domains. The 
JmjC domain is the catalytic domain and is therefore required for demethylase activity in this 
KDM4 subfamily. Structural integrity of the protein is provided by the JmjN domain, which also 
interacts with the catalytic domain. The PHD and Tudor domains act as reader domains and 
recognize specific methylated lysines. The KDM4A Tudor domains recognize and bind 
H3K4me2/me3 and H4K20me2/me3 whereas the PHD domains bind methylated and unmodified 
residues on many histone tails, providing a more flexible recognition pathway of histone 
modifications. KDM4A-C are known to demethylate H3K9me2/me3 and H3K36me2/me3, 
where KDM4D and –E demethylate only H3K9me2/me3. Crystallography has shown differences 
in the surface residues of the peptide binding pocket between KDM4A-C and KDM4D-E.  The 
structural variation within the peptide binding pocket of KDM4 isoforms alters the electrostatic 
properties causing interactions with peptides to be disrupted. The variation of peptide-enzyme 
interactions may explain the difference in activity toward H3K36 [26].  
KDM4A demethylates trimethylated lysine residues more efficiently than dimethylated 
residues and has approximately 5-fold higher activity towards H3K9me3 than H3K36me3. X-ray 
crystallography analysis of KDM4A has shown that the electrostatic environment in the methyl 
group-binding pocket does not allow productive positioning toward the iron-containing catalytic 
domain of the methyl group on monomethylated lysine residues. This further supports the 
methylation state specificity of these KDM4 proteins [27-29].  
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1.6 KDM4 DEMETHYLATION MECHANISM 
The KDM4 proteins are JmjC domain containing demethylases requiring Fe(II), 2-KG and 
molecular oxygen (O2) for the catalysis of a dioxygenase reaction that results in demethylated 
lysine residues on histones. In the active site, first a His-Glu/Asp-His triad positions the Fe(II) 
and then 2-KG and oxygen bind forming oxoferryl (IV) which is highly reactive. 2-KG is 
decarboxylated and the result is succinate and CO2. The methyllysine target is hydroxylated 
resulting in an unstable intermediate (hydroxymethyl moiety), which spontaneously decomposes 
to formaldehyde and the demethylated product in either the di- or mono- methylated state. The 
released formaldehyde is oxidized by FDH, which also reduces NAD+ to NADH [27-29]. Figure 
2 depicts the JmjC domain containing demethylation mechanism. 
Figure 2: JmjC domain containing demethylase mechanism. 
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1.7 KDM4 EXPRESSION 
The normal expression patterns of the KDM4 genes suggest that the associated proteins have 
non-overlapping biological functions in diverse cell types and are regulated by distinct pathways. 
KDM4A-C are ubiquitously expressed in human tissues with the highest expression being in the 
spleen, ovaries and colon. KDM4A and –C are expressed 3-6 fold greater than KDM4B.  KDM4D 
and KDM4E are mainly expressed in the testes, but KDM4E expression is low relative to the 
other KDM4 genes. To elucidate physiological functions of this subfamily, knockout and 
transgenic models have been established. Homozygous mutants of KDM4A and B in Drosophila 
are not viable and die. Heart-specific knockout of KDM4A and transgenic models in mice results 
in cardiac hypertrophy.  Conditional knockout of KDM4B in specific cell types results in delayed 
tissue development (e.g. mammary epithelial cells). Interestingly, knockout of KDM4B or 
KDM4D in mouse models are compatible with life and do not show extreme abnormalities [27-
29].  
The KDM4 family is known to have important functions during development. 
Specifically, they maintain the state of euchromatin necessary for efficient proliferation and 
differentiation in embryonic stem cells. During development, the specific functions of KDM4 
proteins are widespread with the promotion of pluripotency and differentiation both observed to 
be regulated by these proteins. Various tissues rely on the proper functioning of the KDM4 
proteins. For instance KDM4A directs embryonic skeletal cell differentiation, KDM4B directs 
bone cell differentiation and KDM4C directs fat cell differentiation. A pluripotent state can be 
achieved through KDM4 proteins interacting with or promoting the expression of pluripotency 
factors such as c-Myc, Oct4 and Sox2. Oct4 and Sox2 are involved in an expression feedback 
loop that is required for the de-differentiation of adult stem cells. The signaling involved within 
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the feedback loop is eliminated when KDM4C expression is absent and Oct4 expression is 
decreased when the cells lack KDM4A [27-29].  
1.8 REGULATION OF KDM4 PROTEINS 
Cells have various mechanisms to control the KDM4 protein activity, expression and 
localization, which is not surprising based on the family having significant biological impact. 
There are pathways, transcription factors, hormones and protein complexes that are involved in 
the regulation of the KDM4 proteins. The ubiquitination pathway can regulate KDM4A and 
KDM4B during cell cycle progression in response to DNA damage. Two SCF (Skp, Cullin, F-
box containing) complexes: SKP1-CU11-FBox and FBXO22 regulate KDM4A during cell cycle 
progression by controlling its ubquitination and inducing protein degradation. RNF8 and 
RNF168 complexes of the ubiquitination pathway are involved in the regulation of KDM4A-B 
when DNA damage has been detected.  PARP-1 can act on the KDM4A-D affecting the H3K9 
demethylation function by poly(ADP-riboxyl)ating the glutamic acid residues within the 
proteins. The demethylation activity of KDM4C is also regulated by IP6K1, which induces the 
dissociation of KDM4C [30-33].   
Transcription factors, such as HIF1, can also regulate KDM4B and C. HIF1 is a protein 
that responds to hypoxia to regulate cellular and systemic homeostasis. In breast cancer, HIF1-
alpha interacts with KDM4C resulting in the recruitment of HIF1-alpha target gene response 
elements. Androgens can regulate KDM4B activity, which will affect androgen receptor 
transcriptional activity through demethylation or androgen receptor ubiquitination [34-35].  
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Homodimers and heterodimers of the KDM4 protein members can form resulting in 
another regulatory mechanism. KDM4A-C can become incorporated into multiprotein 
complexes with the SWI/SNF chromatin-remodeling complex and can interact with inhibitory 
complexes such as histone deacetylase complexes (HDACs). The formation of dimers and 
incorporation into functionally diverse multiprotein complexes supports that KDM4 proteins 
have a significant role in directing gene expression in development, homeostasis and pathology 
[36-38].  
1.9 KDM4 MEMBERS AND CANCER 
The overexpression or underexpression on the gene and protein level of the KDM4 subfamily 
has been implicated in various cancers. There have been large analyses of cancer copy number 
profiles and findings by independent research groups studying the proteins to support the 
involvement of this family in cancer development or progression.  
KDM4A overexpression and amplification is seen in several cancers such as ovarian, 
breast, squamous cell carcinomas, prostate, lung and colon cancer [39-43]. KDM4A 
overexpression in tumors triggers localized chromosomal instability, specifically 1q12, 1q21 and 
Xq13.1 copy gains, which are rich with oncogenes. Overexpression of KDM4A can lead to these 
localized copy gains by extending S phase via reducing HP1y binding to chromatin. When HP1y 
cannot bind to chromatin, it results in an open, accessible chromatin state allowing for the re-
replication of oncogenic regions. HP1y bound to chromatin hinders KDM4A from being able to 
modify histones. The antagonistic behavior between KDM4A and HP1y may contribute to the 
explanation as to how KDM4A encourages DNA replication [39]. Overexpression of KDM4 
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proteins also disrupts the DNA mismatch repair (MMR) pathway resulting in poor chromatin 
integrity. Mismatch recognition proteins bind H3K36me3 to ensure proper DNA MMR occurs. 
When KDM4C is overexpressed, H3K36me3 is less abundant hindering mismatch recognition 
proteins from binding appropriate regions. The dysregulated pathway allows for mutations to go 
overlooked and promote genome instability. Proper DNA MMR can be restored through the 
downregulation of KDM4C. Because KDM4A and KDM4B demethylate H3K36me3, similar 
results are expected with the overexpression of these proteins [40].   
KDM4A overexpression can also allow cells to evade apoptosis or decreases apoptosis all 
together by extending the G2/M phase. The activating protein 1(AP1) transcription factor is a 
heterodimer of the JUN and FOS proteins, which controls apoptosis, cell proliferation and 
differentiation. The activity of AP1 is induced by a positive feedback loop where KDM4A is a 
priming factor. KDM4A can indirectly induce the expression of AP1 genes because histone 
demethylation facilitates AP1 binding to JUN and FOSL1 promoters, which stimulates the 
feedback loop. The overexpression of KDM4A can result in the overexpression of AP1 genes, 
which will promote cell growth and metastasis [41].  
KDM4A can also repress the expression of tumor suppressors, such as CHD5, by 
impeding senescence. KDM4A can directly bind with tumor suppressors (e.g. p53) rendering 
them inactive and can form complexes with the androgen and estrogen receptors making them 
more sensitive resulting in the overexpression of oncogenes. ER-positive breast cancer cells with 
depleted KDM4A showed decreased expression of oncogenes c-Jun and cyclin D1. Proliferation 
inhibition of ER-negative and ER-positive breast cancer cells was observed with KDM4A 
knockdown. These results show that KDM4A is necessary for ER-positive and –negative breast 
cancer and supports the idea that there are multiple pathways that KDM4A is involved in, which 
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can influence breast cancer development and/or progression. Contrasting with the results for 
breast cancer, the overexpression of KDM4A in HeLa cervical carcinoma did not result in tumor 
growth. With opposing results for the overexpression of KDM4A in different cancer cell lines, 
general conclusions cannot be made based on the expression of this protein, but rather it is 
cancer and tissue specific [28, 38-43].  
KDM4B plays a significant role in nuclear receptor responsiveness in breast and prostate 
cancer. KDM4B is highly expressed in estrogen receptor (ER)-positive breast cancer subtypes, 
can bind to the ER, act on the repressive mark of H3K9me3, and recruit chromatin remodeling 
complexes. The activity of KDM4B when bound with the ER can induce oncogenic expression 
(e.g. MYB and MYC) resulting in proliferation. KDM4B expression level is positively correlated 
with prostate cancer severity, potentially due to it interactions with the androgen receptor (AR). 
AR transcription is upregulated and the AR is stabilized when cooperating with KDM4B via 
degradation inhibition. KDM4B is involved in metastasis and hypoxia and can promote cell 
survival [35, 44-46]. 
The overexpression of KDM4C has been observed in breast and prostate cancer, 
esophageal squamous cell carcinoma, metastatic lung sarcomatoid carcinoma, non-solid tumors 
and medulloblastoma. KDM4C can promote tumorigenesis by activating oncogenes (e.g. 
MDM2), binding the AR nuclear receptor and establishing stem cell-like phenotypic 
characteristics. Overexpression of KDM4C resulted in hypomethylation of H3K9 and 
knockdown studies in breast cancer cells results in the inhibition of proliferation and metastasis 
[47-49].  
It has become clear that the KDM4 subfamily members play various and diverse roles in 
cancer development and progression. The dysregulation of KDM4 proteins have been correlated 
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to other diseases due to the disruption of cellular functions. Upregulation of KDM4A has been 
associated with cardiac anomalies and the progression of viral infections and SNPs within 
KDM4C genes are correlated with autism. The functions of the KDM4 proteins are widespread 
and not fully understood, but continue to be elucidated [50-52]. 
1.10 KDM4A INHIBITORS AND THERAPEUTICS 
Many histone demethylase inhibitors have been designed and are classified into five groups: 2-
ketoglutarate analogs, iron chelators, zinc chelators, catalytic domain inhibitors, and prodrugs. 
N-oxalylglycine (NOG) and its derivatives are analogs of 2KG and are competitive inhibitors of 
the KDM4 family.  Another competitive 2KG analog inhibitor is 2-hydroxyglutarate (2-HG), 
which is an oncometabolite. The reported therapeutic inhibitors lack selectivity and specificity 
towards histone demethylases, which becomes problematic regarding nondesirable targets. 
Therapeutic inhibitors for histone demethylases remain in the preclinical phase [53-55].  
1.11 KDM4 AND PUBLIC HEALTH 
With epigenetics rapidly expanding and implicated in critical biological mechanisms it is 
important to understand the enzymes involved. The JmjC domain-containing proteins include 
several subfamilies each containing multiple isoforms. The KDM4 subfamily has been and 
continues to be extensively studied because its members have been observed in various 
pathologies and involved in many mechanisms such as the regulation of DNA replication, gene 
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expression, transcription and cell cycle progression. Because KDM4A overexpression is 
observed in several types of cancer and results in various phenotypes, increased understanding of 
this enzyme will contribute to improving public health.  
1.12 ALLELE SPECIFIC APPROACH 
Approximately 30,000 protein-coding genes give rise to massive diversity among proteins, 
which are responsible for the complex biochemical processes that occur within the human body. 
Many of these proteins share similar structures and domains allowing them to use the same 
cofactor while having a different function. This idea is true for many above-mentioned 
demethylases that require 2-ketoglutarate as a cofactor. Families of proteins often contain the 
same domains, which allow the human body to be more efficient, but make studying the 
function, localization and impact of a specific protein increasingly difficult.  
Various techniques and approaches have been applied to understand the role of specific 
proteins such as introducing single nucleotide mutations (for gain- or loss-of function) and 
knockout/knockdown and observing the phenotypic effects. These techniques have been 
beneficial, but the conclusions are limited based on the observations. It is known that many 
protein-protein complexes form to carry out many processes, there are compensatory 
mechanisms in place for adaptability and biological processes often occur on the millisecond to 
minute time scale (e.g. PTMs). With these characteristics and biological mechanisms in place, it 
is challenging to determine if the phenotypic effects are due to the under- or overexpression of 
the targeted protein or if there is involvement from other proteins that is not being monitored. 
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Therefore, it is necessary to use approaches that can be more specific, controlled and timely to 
monitor the function of a protein.  
Allele-specific chemical genetics (ASCG) incorporates different design strategies to 
develop systems to study widespread proteins and associated ligands. The approaches most 
commonly used are electrostatic, steric, covalent and unnatural amino acid mutagenesis and all 
of them involve incorporating novel interactions between the protein and ligand that has been 
engineered.  
The approach used in this study is steric complementation, aka Bump-Hole approach. 
The principle of this study design is to engineer the protein of interest and its associated ligand to 
create a complementary shape between them. A bulky group is introduced onto the ligand 
(Bump) and is accommodated by the space (Hole) created through site directed mutagenesis on 
the enzyme. The native enzyme due to steric hindrance will not accept the bulky ligand and the 
engineered enzyme will not accept the native ligand because of lack of shape/ size 
complementarity. This creates an allele specific activator or inhibitor for the modified enzyme 
that can be used to monitor isoforms within the same family in a completely independent fashion 
(Figure 3) [54].   
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Figure 3. Allele Specific Bump-Hole Approach Scheme 
Figure 3 shows the bump-hole approach where the native enzyme is mutated forming a ‘hole’ in 
the binding pocket and the cofactor is modified to incorporate a ‘bump’ that will be 
complementary to the hole containing enzyme.  
1.13 OBJECTIVES 
It is essential to understand the mechanism and be able to monitor each KDM4 isoform 
independently due to their differential expression, non-redundant functions, disease-specific 
activity and temporal activity. The allele-specific approach is more appropriate than previous 
methods for studying protein isoforms in the same family because of its rapid effect. For 
example, RNAi takes more than 10 hours for the method to take effect, whereas the allele-
specific approach is on the nanosecond scale. This is relevant because many biological 
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mechanisms are time-dependent and takes only seconds (e.g. PTMs) or minutes (e.g. mitosis) to 
occur.  
The main objective of this project is to develop an engineered system for KDM4A in 
vitro that is allele specifically activated. The system will involve engineering the catalytic 
domain of KDM4A and the fourth carbon of 2-KG, which will act independently of and not 
influence the native KDM4A-2KG pair. The engineered pair should be site and state specific, 
similar to the native pair. This engineered system should be able to mimic the native KDM4A 
system and should give consistent results in the KDM4 isoforms. First, the Bump-Hole approach 
will be used to create the engineered system and all engineered proteins and 2-KG analogs will 
be screened for enzymatic activity in the presence of trimethylated histone peptides. The 
substrate specificity will be tested with the engineered system(s) that show similar activity to the 
native system. The Km for each engineered pair with substrate specificity will be compared to the 
Km of the native system. Next, the KDM4A-mutant-2KG analog pair with similar activity to the 
native system, but independent of it, will be applied to an in vitro coupled assay mimicking the 
reading, writing and erasing cycle. Finally, the engineered mutant with the most similar activity 
to the native will be applied to other members within the KDM4 subfamily, which will be tested 
with significant 2-KG analogues in vitro. Below is a list of objectives to fulfill the main goal of 
developing an allele specific engineered KDM4A-2-KG pair:  
1. Generate engineered KDM4A catalytic domain and 2-ketoglutarate analogues
2. Perform screening of engineered KDM4A-2KG pairs for bioorthologous system
3. Test bioorthologous system in KDM4 isoforms for conservation of results
4. Determine if KDM4A substrate specificity remains intact for engineered
system(s)
25 
5. Determine if engineered KDM4A-2KG pair(s) are catalytically competent
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2.0  MATERIALS AND METHODS 
2.1 PLASMIDS 
The catalytic domain of the human KDM4A plasmid was obtained from addgene (cat# 38846) 
and includes an N-terminal hexahistidine tag (HHHHHH) and kanamycin resistance (the native 
KDM4A catalytic domain will be referred to as KDM4A-WT). The catalytic domains KDM4A, 
B and D were obtained from Raymond Trievel’s group and include an N-terminal strep tag 
(WSHPQFEK) and ampicillin resistance. The plasmids were purified as described above and 
verified through sequencing. All plasmids were purified using Fisher Scientific GeneJet Plasmid 
Miniprep Kit and the concentrations were measured using EppendorfTM BioSpectrometer. The 
purified plasmids were sent for sequencing through the University of Pittsburgh’s Genomics 
facility or GeneWiz. The nucleotide sequencing data was translated to the corresponding amino 
acid sequence and aligned with the associated NCBI FASTA sequence to verify that the 
sequence is correct.  
2.2 SITE DIRECTED MUTAGENESIS 
The primers (Table 3) for site directed mutagenesis were designed using Agilent Technologies 
QuikChange Primer Design Tool (http://www.genomics.agilent.com/primerDesignProgram) and 
the Integrated DNA Technologies OligoAnalyzer 3.1 (http://www.idtdna.com/calc/analyzer). 
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Site directed mutagenesis (SDM) was done using the QuikChange Lightning Kit (Table 4). The 
PCR products were treated with DPNI to digest the parent plasmid and then transformed in 
XL10-Gold ultracompetent cells with β –mercaptoethanol (BME) to enhance transformation 
efficiency. The transformed plasmids were then inoculated in LB-broth and grown overnight at 
37°C while shaking at 225 RPM. KDM4A mutants will be referred to as ‘KDM4A-mutation’ 
(e.g. KDM4A-Y132A). To verify the mutation was successfully incorporated, the plasmid was 
sent for sequencing through GeneWiz.  
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Table 3. Site Directed Mutagenesis Primers 
Above is a list of primers designed for Site Directed Mutagenesis. Reverse primers used are the 
reverse complement to the forward primer. Mutations coding for the amino acid change are bold 
and underlined. 
MUTATION FORWARD PRIMER 
KDM4A-Y132A 5'-CATTCAATCCTCCAATCGCCGGTGCAGATGTGAATGG-3'
KDM4A-Y132G 5'-CATTCAATCCTCCAATCGGCGGTGCAGATGTGAATGG-3'
KDM4A-Y175A 5'-GAGGGTGTGAACACCCCAGCCCTGTACTTTGGCATG-3'
KDM4A-Y175G 5'-GGTGTGAACACCCCAGGCCTGTACTTTGGCATG-3'
KDM4A-Y177A 5'-GTGAACACCCATACCTGGCCTTTGGCATGTGGAAGAC-3'
KDM4A-Y177G 5'-GTGAACACCCCATACCTGGGCTTTGGCATGTGGAAGAC-3'
KDM4A-F185A 5'-GGCATGTGGAAGACATCCGCCGCTTGGCACACTGAAGA-3'
KDM4A-F185G 5'-GGCATGTGGAAGACATCCGGCGCTTGGCACACTGAAG-3'
KDM4A-F185I 5'-GGCATGTGGAAGACATCCATCGCTTGGCACACTGAAG-3'
KDM4A-F185T 5'-GGCATGTGGAAGACATCCACCGCTTGGCACACTGAAG-3'
KDM4A F185V 5'-GGCATGTGGAAGACATCCGTGGCTTGGCACACTGAAG-3'
KDM4A-N198A 5'-GACCTCTACAGCATCGCCTACCTGCACTTTGG-3'
KDM4A-N198G 5'-GGACCTCTACAGCATCGGCTACCTGCACTTTGGAG-3'
KDM4A-K206A 5'-CTGCACTTTGGAGAACCAGCCTCCTGGTACTCTGTTCC-3'
KDM4A-K206G 5'-CTGCACTTTGGAGAACCAGGCTCCTGGTACTCTGTTCC-3'
KDM4A-W208A 5'-CTTTGGAGAACCAAAGTCCGCCTACTCTGTTCCACCTGAG-3'
KDM4A-W208F 5'-GGAGAACCAAAGTCCTTCTACTCTGTTCCACCTGAG-3'
KDM4A-W208G 5'TGGAGAACCAAAGTCCGGCTACTCTGTTCCACC-3'
KDM4A-W208V 5'GGAGAACCAAAGTCCGTGTACTCTGTTCCACCTG-3'
KDM4A-A286G 5'-CCATGGTTTTAACTGTGGCGAGTCTACCAATTTTGC-3'
KDM4A-S288A 5'-GGTTTTAACTGTGCGGAGGCCACCAATTTTGCTACCC-3'
KDM4A-S288G 5-GGTTTTAACTGTGCGGAGGGCACCAATTTTGCTACCCG-3'
KDM4B-F186G 5'-CATGTGGAAGACCACCGGCGCCTGGCACAC-3'
KDM4D-F189G 5'- GCATGTGGAAAACCACGGGCGCTTGGCATACAGAG-3'
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Table 4. Cycling parameters for Site Directed Mutagenesis 
The parameters were chosen based on the QuikChange Lightning Site Directed Mutagenesis kit. 
The Elongation period was calculated by giving it 30 seconds/kb of plasmid. PCR products were 
treated with DPNI and then transformed into XL10 Gold Ultracompetent cells or stored in -20°C 
until further use. 
2.3 PROTEIN EXPRESSION AND PURIFICATION 
All plasmids were transformed in a strain of chemically competent E. coli (Table 5) for protein 
expression once the sequencing results verified that the protein sequence was correct and that the 
mutation (if relevant) was in place without disrupting other areas of the protein. The 
transformants were inoculated in 10 ml LB broth and grown overnight at 37°C while shaking at 
225 RPM. The inoculations were then grown in two liters of LB-broth at 37°C to reach an 
optical density (OD600) of 0.6-0.8 (~4 hours) and protein expression was induced with IPTG 
(0.3-1mM). Proteins were expressed overnight at 17°C.  
Step Temperature (°C) Time
Initial denature 95 2 minutes
Denaturing 95 20 seconds
Annealing 60 10 seconds
Elongation 68 4.25 minutes
Final Elongation 68 5 minutes
Storage 4 ∞
Site Directed Mutagenesis
18 cycles 
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The KDM4A native and mutant proteins containing the hexahistidine tag or the strep-tag 
were first purified through Nickel Affinity Chromatography or StrepTactin Affinity 
Chromatography, respectively, using gravity flow columns. Then the fractions containing protein 
observed through SDS-PAGE were purified through Size Exclusion Chromatography using 
Superdex-200 in FPLC. The fractions containing protein supported by SDS-PAGE (Figure 4) 
were concentrated using Millipore centrifugal filter units and the concentration was determined 
using Bradford solution. The proteins were stored in  -80°C until further use.  
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Table 5. E. coli competent cells used for protein expression 
Above are the various E. coli competent cells used to express each protein state. At least two 
liters of protein were express and then purified. 
Protein Expression Cell line
KDM4A-WT BL21 [de3] pLysS
KDM4A-Y132A BL21 [de3] pLysS
KDM4A-Y132G BL21 [de3] Codon plus
KDM4A-Y175A BL21 [de3] pLysS
KDM4A-Y175G BL21 [de3] Codon plus
KDM4A-Y177A BL21 [de3] pLysS
KDM4A-Y177G BL21 [de3] Codon plus
KDM4A-F185A BL21 [de3] pLysS
KDM4A-F185G BL21 [de3] Codon plus
KDM4A-F185I BL21 [de3] Arctic Express
KDM4A-F185T BL21 [de3] Arctic Express
KDM4A-F185V BL21 [de3] Arctic Express
KDM4A-N198A BL21 [de3] Codon plus
KDM4A-N198G BL21 [de3] Arctic Express
KDM4A-K206A BL21 [de3] pLysS
KDM4A-K206G BL21 [de3] Arctic Express
KDM4A-W208A BL21 [de3] pLysS
KDM4A-W208G BL21 [de3] Codon plus 
KDM4A-W208V BL21 [de3] Arctic Express
KDM4A-W208F BL21 [de3] Codon plus
KDM4A-A286G BL21 [de3] Arctic Express
KDM4A-S288A BL21 [de3] Codon plus
KDM4A-S288G BL21 [de3] Codon plus
KDM4A-F185G/Y132A BL21 [de3] Arctic Express
KDM4A-F185G/Y132G BL21 [de3] Arctic Express
KDM4B-WT BL21 [de3] Codon plus
KDM4B-F186G BL21 [de3] Star
KDM4D-WT Rosetta [de3] pLysS
KDM4D-F189G BL21 [de3] Codon plus
PHF8-WT BL21 [de3] Star
JMJD6-WT Rosetta [de3] pLysS
JMJD3-WT Rosetta [de3] pLysS
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Figure 4. Purified Proteins 
Below shows the SDS-PAGE gel of purified proteins. Lanes 1è7 consists of KDM4A-WT, 
KDM4A-F185A, KDM4A-F185G, KDM4B-WT, KDM4B-F186G, KDM4D-WT, KDM4D-
F189G. All proteins used in biochemical assay were at least 90% pure.  
2.4 HISTONE PEPTIDE PREPARATION 
The University of Pittsburgh’s Peptide Synthesis Facility synthesized the histone peptides (Table 
6). Crude histone peptides were purified through HPLC (Table 7) and concentrated by speedvac 
and lyophilyzation. The peptides were dissolved in H2O + 0.1% TFA and stored in -80°C. The 
peptide concentration was determined using EppendorfTM Biospectrometer at 205nm and verified 
through MALDI using CHCA matrix. All peptides were stored in -80°C until used for 
downstream biochemical assays. 
 1         2          3          4         5          6           7 kD 
260 
140 
100 
70 
50 
40 
35 
25 
15 
10 
Protein
KDM4A-WT
KDM4A-F185A
KDM4A-F185G
KDM4B-WT
KDM4B-F186G
KDM4D-WT
KDM4D-F189G
MW (kD)
44.270
44.190
44.180
43.340
43.250
41.160
41.070
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Table 6. Histone Peptides 
The histone peptides used as substrates for the assays performed are shown below with their 
associated amino acid sequence and molecular weight (daltons). 
Table 7. Histone peptide purification 
The histone peptides listed in Table 6 were purified through HPLC using the conditions shown 
below. Peptides Eluted between 7 and 10 minutes.  
Peptide SEQUENCE MW (Da)
H3K4me3 H2N-ARTK(Me3)QTARKSTGGKAPRKQLK(biotin)-CO2H 2692
H3K9me3 H2N-ARTKQTARK(Me3)STGGKAPRKQLK(biotin)-CONH2 2693
H3K36me3 H2N-KSAPSTGGVK(Me3)KPHRYKPGTGK(biotin)-CONH2 2562
H3K9 !TO!BE!ADDED 2723
H3K27me3 H2N-APRKQLATKAARK(Me3)SAPATGGVK(biotin)-CONH2 2475
H3R2me2 H2N-AR(Me2)TKQTARKSTGGKAPRK(biotin)-CONH2 2195
Peptide Purification HPLC conditions 
Time 
% Water + 0.1% TFA 
% 
ACN 
Initial 100 0 
15 min 91 9 
18 min 100 0 !
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2.5 2-KETOGLUTARATE AND 2-KETOGLUTARATE ANALOG PREPARATION 
Various 2-ketoglutarate analogs, including the native molecule, were purified through HPLC 
after being synthesized by colleagues. The HPLC fractions were concentrated by speedvac and 
lyophilization and then suspending the solid in H2O + 0.1% TFA to make 25mM concentration.  
The 2-KG analogs were verified through LC/MS (ESI-negative) and stored in -20°C.  
2.6 MALDI DEMETHYLASE ASSAY 
To monitor enzymatic activity, a demethylase assay was optimized and then observed through 
MALDI. All contents except for 2-KG were added together in a microcentrifuge tube and briefly 
centrifuged. The 2-KG was then added to the microcentrifuge tube and briefly centrifuged again. 
The MALDI demethylase assays were performed at 37°C over a three hour time period. The Iron 
(II) ammonium sulfate and L-ascorbic acid were made fresh every two hours.  The modification 
state of the peptide was observed using MALDI with CHCA matrix. The MALDI plate was 
analyzed using Voyager on the Reflector Positive mode. The negative control included all 
components of the assay except for the demethylating enzyme. A schematic of the MALDI 
demethylase assay is shown in Figure 5 and the components of the assay are listed in Table 8. 
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Figure 5. MALDI Demethylase Assay Scheme 
Below is the MALDI demethylase assay scheme showing the steps to perform the assay. The 
compilation of all assay components in a microcentrifuge to a total volume of 20 ul was 
centrifuged and then incubated for three hours in 37°C. After the assay was completed, a sample 
was transferred onto the MALDI plate with CHCA matrix and analyzed. 
Table 8. MALDI Demethylase Assay Components 
A complete list of the MALDI demethylase assay components are shown below. The Iron (II) 
sulfate and L-ascorbic acid were made fresh (every two hours) to optimize results. The 2-KG 
was added to the cocktail last.  
20#ul#
10 uM peptide 
10 uM enzyme 
1 mM 2-KG 
37°C Incubator 
3 hrs 
#
#
#
#
MALDI PLATE 
1 ul sample  
1 ul CHCA matrix 
Tris-HCl pH8 50 mM
(NH4)2SO4 FeSO4 50 uM
2-KG 1 mM
L-ascorbic acid 2 mM
Histone peptide 10 uM
KDM4A enzyme 10 uM
ddH20 to vol to volume
Total vol: 20 ul
MALDI Demethylase Assay
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2.7 COUPLED METHYLATING-DEMETHYLATING ASSAY WITH G9A 
This assay involves, first, methylating a histone peptide using G9A methyltransferase and SAM 
(universal methyl donor) and, second, demethylating the newly methylated histone peptide via 
KDM4A-2KG system (native or engineered). H3K9-biotin peptide was incubated with G9A and 
SAM for 1 hour at room temperature (Table 9). A sample for MALDI analysis was taken to 
verify that trimethylation occurred. Streptavidin beads were added to the methylation assay to 
pull down the methylated histone peptide and washed three times (50 mM Tris, pH 8). Following 
centrifugation and removal of supernatant, the demethylase assay was applied using the same 
conditions stated earlier, but with a 50 ul demethylase assay volume and a four hour incubation 
period. After completion of the demethylase assay, the reaction was centrifuged and supernatant 
was removed. The beads were washed as previously described and the peptide was eluted with 
ACN + 0.1% TFA. The methylation status of the peptide was observed through MALDI (Figure 
6). 
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Figure 6. Coupled Methylating-Demethylating Assay Scheme 
Coupled methylating-demethylating assay schematic showing the flow of the reaction is below. 1 
represents G9A methylating H3K9, 2 is the peptide pull-down and wash step to prepare for stage 
3, which is the demethylating stage applied as described earlier, but with an assay volume of 50 
ul and a 4 hour incubation period. 
50 ul 
10 uM peptide 
10 uM enzyme 
1 mM 2-KG 
37°C Incubator 
4 hrs 
!
!
!
!
MALDI PLATE 
1 ul sample  
1 ul CHCA matrix 
100 ul 
10 uM H3K9 
2 uM G9A 
50 uM SAM 
Incubator 
1 hour at Room Temp 
!
!
!
!
MALDI PLATE 
1 ul sample  
1 ul CHCA matrix 
Check for trimethylated product Streptavidin 
beads 
Shake 1 hour at Room 
Temp  
Wash with 50mM Tris 
(3X) 
1 
2 
3 
Repeat Wash 
step and elute 
with ACN 
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Table 9.  Components of the Methylation Assay 
A list of components for the methylation portion used in the coupled methylating-demethylating 
assay is shown below.    
2.8 DETERMINING KM OF 2-OG3 AND 2-OG7
The catalytic efficiency of engineered KDM4A-2KG systems were compared to the native 
KDM4A-2KG by varying the concentration of 2KG in the demethylase assay described above. 
The concentration of 2KG ranged from 10 uM to 1mM. All other conditions of the MALDI 
demethylase assay remained the same, but the incubation period was 1.5 hours to eliminate the 
confounding effect of saturation. The Km was determined using PRISM. Assays were done in 
duplicates.  
Tris HCl pH 8 50mM
ddH2O to 100 ul
H3K9-biotin 10uM
SAM 50uM
G9A 2uM
Methylation Assay
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3.0  RESULTS 
3.1 ALLELE SPECIFIC ACTIVATION OF KDM4A 
The bump-hole technique requires engineering a ‘hole’ in the enzyme, KDM4A, and a ‘bump’ in 
the 2KG cofactor. Several of the amino acids within the catalytic domain of KDM4A are bulky, 
such as tryptophan and tyrosine and make good targets to mutate to make a hole suitable for the 
‘bump’ incorporated onto the 2KG cofactor. When several mutants have been created, providing 
the ‘hole’, and many cofactor analogues have been synthesized, providing the ‘bump’, each 
system can be screened for enzymatic activity. Each KDM4A protein expressed (native and 
mutants) was screened for catalytic activity with each 2-KG molecule (native and analogs) using 
MALDI. 
3.2 GENERATION OF KDM4A VARIANTS 
The amino acids to target for mutagenesis were chosen based on the KDM4A structure reported 
on the protein database (PDB code: 2YBS). When looking at the crystal structure (Figure 7), it is 
evident that the 2-KG cofactor and the histone peptide are in close proximity within the binding 
pocket. It was important to target amino acids within the binding pocket that would not disturb 
peptide binding, but would be complementary to an engineered 2-KG compound. The mutants 
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designed included a single amino acid change from the native to an alanine, glycine or valine 
because these residues are relatively small, which will incorporate a ‘hole’ in the enzyme. There 
were 24 KDM4A mutants generated which were all verified through sequencing.  
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Figure 7. Structure and Sequence of KDM4 proteins 
Top: Crystal Structure of 2-Ketoglutarate and methylated lysine binding pocket of the catalytic 
domain for KDM4A (PDB: 2YBS). The left image shows the entire KDM4A catalytic domain 
and the right image is a zoomed in image of the binding pocket within the catalytic domain.  
Middle: Amino acid targets for mutagenesis. Aqua: Amino acid residues to mutate, Yellow: 
2KG, Purple: trimethylated lysine residue.  
TRP-208
LYS-206
ASN-198 SER-288
ALA-286
TYR-175
TYR-177
TYR-132
PHE-185
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Bottom: Sequence alignment comparing a segment of the catalytic domain of KDM4 
isoforms using ClustalW-Omega. Arrow indicates sequence homology at specific amino acid 
residue: Phe-185. 
3.3 GENERATION OF 2-KG ANALOGUES 
The cofactor for JmjC domain containing proteins is 2-ketoglutarate and was modified to 
incorporate a ‘bump’ that would be complementary to the hole generated in the enzyme. In total, 
there were 12 2-KG analogues synthesized and purified (Figure 8). The bumped cofactors will 
all be screened with the native KDM4A enzyme and with all the hole-containing KDM4A 
mutants to determine if there is complementarity for demethylation activity.  
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Figure 8: 2-Ketoglutarate Analogues 
The 2-ketoglutarate analogues were synthesized, purified by HPLC and verified using LCMS. 
Bumped analogues have the modification located on the 4-carbon. Each residue will be 
referenced throughout the document using the bold number indicated above the structure. 
3.4 SCREENING OF KDM4A MUTANTS AND 2KG ANALOGUES 
With 24 KDM4A mutants and 12 cofactor analogues generated, there were 288 engineered 
enzyme-cofactor pairs screened for complementary bump-hole configuration. All 24 KDM4A 
mutants were paired with the native 2-KG compound and KDM4A-WT was paired with all 12 2-
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KG analogues to screen for a bioorthogonal system using MALDI (Figure 9). KDM4A-WT did 
not show catalytic activity with any of the 2-KG analogs, whereas, 9 of the KDM4A-mutants: 
F185A, F185I, N198A, N198G, W208F, W208G, W208V, A286G and S288A showed catalytic 
activity with 1. Half of the incorporated mutations resulted in no catalytic activity when paired 
with any of the 2-KG compounds. Three KDM4A mutations, all at the same amino acid: Phe-
185, provided bioorthogonal systems. These mutations include KDM4A-F185G, F185T and 
F185V. KDM4A-F185G and F185T are catalytically active with 11 of the 2-KG analogues, 
whereas KDM4A-F185V is active with only five and at a significantly lesser amount. Peptide 
modification status for all KDM4A-F185 mutants that showed activity with any 2-KG analog 
were characterized and compared to the native KDM4A-2KG system (Figures 10 and 11).  
KDM4A-F185G and F185T were of the high interest because they were not active with the 
native 2-KG compound. When paired with 3 and 7, KDM4A-F185G demethylation activity 
resulted in the modification status most similar to the native system and will be used for future 
experiments.  
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Figure 9a. Heat map of the Screening results for Engineered KDM4A-2-KG (1-6) pairs 
Above is showing the catalytic activity of each KDM4A-2KG pair towards H3K9me3-biotin 
peptide. Active pairs are highlighted with a blue spectrum of light to dark correlating will least % 
modified (>0%) to greatest percent modified (100%), respectively.  Pairs showing no activity are 
shaded grey. Mutants highlighted in red provide bioorthologout systems. 
1 2 3 4 5 6
ENZYME
KDM4A-WT 100 0 0 0 0 0
Y132A 0 0 0 0 0 0
Y132G 0 0 0 0 0 0
Y175A 0 0 0 0 0 0
Y175G 0 0 0 0 0 0
Y177A 0 0 0 0 0 0
Y177G 0 0 0 0 0 0
F185A 71 100 100 100 87 83
F185G 0 94 100 85 71 72
F185T 0 70 71 55 17 44
F185I 30 0 0 0 0 0
F185V 0 0 13 17 0 0
N198A 84 0 0 0 0 0
N198G 92 0 0 0 0 0
K206A 0 0 0 0 0 0
K206G 0 0 0 0 0 0
W208A 0 0 0 0 0 0
W208G 0 0 0 0 0 0
W208V 44 0 0 0 0 0
W208F 61 0 0 0 0 0
A286G 89 0 0 0 0 0
S288A 68 0 0 0 0 0
S288G 0 0 0 0 0 0
F185G + Y132A 0 0 0 0 0 0
F185G + Y132G 0 0 0 0 0 0
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Figure 9b: Heat map for Screening of Engineered KDM4A-7-13 pairs. 
Above is showing the catalytic activity of each KDM4A-2KG pair towards H3K9me3-biotin 
peptide. Active pairs are highlighted with a blue spectrum of light to dark correlating will least % 
modified (>0%) to greatest percent modified (100%), respectively.  Pairs showing no activity are 
shaded grey. No activity was observed for any pairs involving 9 (data not shown). Mutants 
highlighted in red provide bioorthologout systems. 
7 8 10 11 12 13
ENZYME
KDM4A-WT 0 0 0 0 0 0
Y132A 0 0 0 0 0 0
Y132G 0 0 0 0 0 0
Y175A 0 0 0 0 0 0
Y175G 0 0 0 0 0 0
Y177A 0 0 0 0 0 0
Y177G 0 0 0 0 0 0
F185A 100 80 68 43 100 60
F185G 96 71 50 41 79 79
F185T 33 17 26 13 35 35
F185I 0 0 0 0 0 0
F185V 23 0 13 0 20 0
N198A 0 0 0 0 0 0
N198G 0 0 0 0 0 0
K206A 0 0 0 0 0 0
K206G 0 0 0 0 0 0
W208A 0 0 0 0 0 0
W208G 0 0 0 0 0 0
W208V 0 0 0 0 0 0
W208F 0 0 0 0 0 0
A286G 0 0 0 0 0 0
S288A 0 0 0 0 0 0
S288G 0 0 0 0 0 0
F185G + Y132A 0 0 0 0 0 0
F185G + Y132G 0 0 0 0 0 0
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Figure 10: MALDI Spectrum of KDM4AWT/F185G Demethylation Activity 
MALDI spectrum KDM4A-WT and KDM4A-F185G with 2-KG analogues: 1, 3 and 7. 
Enzyme-cofactor pairs were screened for activity towards H3K9me3-biotin (2692 Da). 
Demethylated products will show a mass change of -14D (me2 = 2678, me1 = 2664). 
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Figure 11: H3K9 Methylation State Profiling Post KDM4A-F185 Mutant Activity 
Bar graphs representing the modification states, mono- (blue), di- (red) and tri-methylated (blue), 
of H3K9. KDM4A-WT and KDM4A-F185-mutants were paired with each 2-KG analog and 
screened for activity towards H3K9me3-biotin peptide. Activity was measured using MALDI.   
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3.5 SCREENING OF KDM4B AND -D MUTANTS AND 2KG ANALOGUES 
The discovery of an engineered KDM4A-2-KG pair that mimics the native pathway is exciting 
and leads to the generation of the same mutant in the KDM4 isoforms to determine if the effect 
will be conserved. The phenylalanine at the 185 position in KDM4A align with the Phe-186 and 
Phe-189 in KDM4B and KDM4D, respectively (Figure 7). The corresponding phenylalanine 
residues were mutated to glycine (KDM4B-F186G and KDM4D-F189G). The native and mutant 
isoforms were screened for catalytic activity on H3K9me3-biotin with 1, 3 and 7. The 2-KG 
analogues were chosen based on the results from KDM4A screening. The native isoforms, 
KDM4B-WT and KDM4D-WT gave similar results to KDM4A-WT, being active with 1 (86% 
and 76% respectively) and inactive with 3 and 7. The mutant residues gave interesting results. 
KDM4B-F185G was not active when paired with 1 and showed activity with 3 (74%) and 7 
(67%). KDM4D-F189G was slightly active with 1 (23%) and highly active with 3 (100%) and 7 
(73%) (Figures 12 and 13). These results may be due to dissimilarities of amino acid residues 
within close proximity to the mutant. For example, there is a serine residue preceding Phe-185 in 
KDM4A, but there is a threonine residue preceding the Phe-186 and Phe-189 in KDM4B and 
KDM4D. 
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Figure 12. Heat Map of KDM4 isoform Activity with 2-KG Analogues 
Below is a summary of the catalytic activity of each KDM4-2KG pair towards H3K9me3-biotin 
peptide. The values within each well represent the percentage of peptide modified 
(demethylated) measured via MALDI.  Active pairs are highlighted with a green spectrum of 
light to dark correlating 
ENZYME 1 3 7
KDM4B-WT 86 0 0
KDM4B-F186G 0 74 67
KDM4D-WT 76 0 0
KDM4D-F189G 23 100 73
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Figure 13: MALDI Spectrums of KDM4 Isoform Activity with 2-KG Analogues 
MALDI spectrum for catalytic domains of KDM4 isoforms, B and D, paired with 2-KG 
analogues 1, 3 and 7.  Enzyme-2-KG pairs were screened for demethylase activity towards 
H3K9me3-biotin and measured using MALDI.  
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3.6 SUBSTRATE SPECIFICITY OF KDM4A-F185G-2KG3/7
Demethylase substrate specificity is of great importance. This characteristic may influence gene 
regulation, protein regulation and development and cell differentiation. Because of the roles 
methylated histones play in various biological mechanisms, it is important to maintain substrate 
specificity when generating a bioorthologous pathway. Substrate specificity was tested to 
observe if the incorporated mutations (Phe>Ala/Gly) affected this characteristic. KDM4A 
specifically targets H3K9me2/3, H3K36me2/3. Both mutations, F185A and F185G, did not show 
any catalytic activity towards H3K4me3, H3K27me3 or H3R2me2 peptides. These mutants 
showed activity towards H3K36me3-biotin peptide, but in a lesser fashion than for H3K9me3-
biotin peptide (data not shown). Also, there is less monomethylated lysine on the peptides (H3K9 
and H3K36) than dimethylated lysine suggesting that the pathway is more efficiently active on 
the trimethylated substrate (Figure 14).  
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Figure 14: KDM4A-F185G substrate specificity 
Below are the MALDI spectrums for non-KDM4A histone substrates when incubated with 
KDM4A-F185G + 3.  Engineered enzyme-cofactor pair was tested with H3K4me3, H3K27me3 
and H3R2me2.    
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3.7 IN VITRO H3K9 METHYLATION BY G9A AND DEMETHYLATION 
BY ENGINEERED ENZYME-COFACTOR PAIR 
Histone lysine residues undergo methylation by various methyltransferases (e.g. G9A) and then 
get demethylated by KDMs. The engineered enzyme-cofactor pairs were tested to see if they 
performed in a similar manner after an unmodified H3K9 histone peptide becomes trimethylated 
by G9A. KDM4A-F185G + 3 and KDM4A-F185G + 7 showed activity towards the newly 
modified H3K9 (Figure 15). The unmodified peptide has a molecular weight of 2723 kD and 
after incubation with G9A and SAM the molecular weight is 2765 kD representing H3K9me3. 
The newly modified peptide was used in the demethylase assay for the engineered pairs and the 
resulting molecular weights were decreased 2765 kD, highest intensity peak at 2751 kD (-me2) 
and small peaks at 2737 kD (-me1). The demethylation activity using 3 and 7 is less than what 
was observed in the previous demethylation assay using the H3K9me3 peptide, which may be 
due to the demethylation cocktail being applied to peptide attached to streptavidin beads.  
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Figure 15. MALDI spectrum of Coupled methylating-demethylating assay 
Spectrums show H3K9 peptide prior to modification (top left),  H3K9me3 peptide product after 
G9A methylating activity (top right), demethylation of H3K9me3 to mono- or di-methylated 
peptide via KDM4A-F185G activity using 2-KG-3 (bottom left) or using 2-KG-7 (bottom right) 
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3.8 DETERMINATION OF KM FOR 2-OG COMPOUNDS 
The Km for the engineered KDM4A-2KG pairs (KDM4A-F185G + 3 or 7) was determined and 
compared to the native system. The same demethylase cocktail was used for the Km
determination experiment, but the concentration of 2-KG compound ranged from 10 uM to 1 
mM and the incubation time was shortened to 1.5 hours to avoid artificial results. The Km for 
KDM4A-F185G + 7 (58.68 ± 11.65) is closer to the Km of the native pathway (27.5 ± 4.823) 
when compared to the Km for KDM4A-F185G + 3 (80.03 ± 18.44) (Figure 16). 
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Figure 16.  Michaelis-Menten Plot for Engineered KDM4A-F185G + 3/7 
Michaelis-Menten plot and data for KDM4A-WT + 2-KG pair (Native pathway), KDM4A-
F185G + 3 pair and KDM4A-F185G + 7 pair. The chart plots the % modified histone peptide 
(considering monodemethylated and didemethylated peptide) vs. the concentration of the 2-KG 
compound. PRISM was used for the analysis of data.  
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4.0  CONCLUSION 
There are 24 JmjC domain containing proteins that are known to have demethylating activity. 
Each of these enzymes demethylate specific substrates at distinct periods of development and in 
certain tissues. The KDM4 subfamily includes KDM4A-E with KDM4F being a pseudogene. 
Each of the KDM4 proteins has pivotal roles in the regulation of gene transcription and 
expression, protein expression and cellular development. The functions of this family have not 
yet been fully understood and the previous approaches to elucidate their functions are limited. 
The KDM4 proteins have widespread and potentially compensatory functions. Many of the 
biological processes these proteins regulate are time dependent and occur in seconds or minutes, 
such as the cell cycle, and to determine the specific roles each KDM4 member plays, an 
approach that can work in this time dependent manner is necessary.  
The allele specific bump-hole method has been applied to the KDM4A pathway. There 
were 24 KDM4A mutants and 12 2-ketoglutarate compounds generated resulting in 288 enzyme-
cofactor pairs screened for a bioorthologous pathway. The engineered KDM4A-F185G + 3 and 7 
have given results that are similar to the native system. The mutation did not disturb the substrate 
specificity seen by its activity with H3K9me2/me3 and its inactivity with H3K4me3, H3K27me3 
and H3R2me2. The results were conserved when the mutation was applied to KDM4B and 
KDM4D except for minimal activity of KDM4D-F189G paired with the native 2-KG compound. 
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Both KDM4A-F185G + 3 and KDM4A-F185G + 7 were active in a system where H3K9 was 
first methylated by G9A and have a Km within a factor of the native system.  
In future experiments, the engineered KDM4A-2-KG pairs should be tested on full 
histone substrates and should be screened with inhibitors. The engineered pair should be tested in 
cell lysates and in live cell culture. This system will lead to the monitoring of KDM4A in vivo 
and elucidate specific functions and genes regulated by this enzyme. 
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APPENDIX: ABBREVIATIONS 
2-KG: (2)-Ketoglutarate 
5hmC: 5-hemimethylcytosine 
5mC: 5-methylcytosine 
AP: Activating Protein 
AR: Androgen receptor
CM: consensus methylation motif   
DNMT: DNA methyltransferase 
DTT: dithiothreitol 
FDH: 10-formyltetrahydrofolate dehydrogenase 
FPLC: Fast protein liquid chromatography 
HIF: Hypoxia inducible factor 
HPLC: High performance liquid chromatography 
IP6K: Inositol hexakisphosphate kinase 
JMJ: JmjC domain containing demethylases 
KDM: Lysine demethylase 
LSD: flavin-dependent lysine specific demethylases 
m6A: N6-methyladenosine 
MBD2: Methylated DNA binding domain-containing protein 
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METTL3: methyltransferase like 3 domain 
MMR: Mismatch repair 
MT: methyltransferase 
NADH: Nicotinamide adenine dinucleotide  
PAD: peptidylarginine deiminases 
PKMT: Protein lysine methyltransferases 
PMT: Protein methyltransferases 
PRMT: Protein arginine methyltransferases 
PTM: Post translational modification 
RNF: Ring finger protein 
SAM: S-adenosylmethionine- binding domain 
SCF: Skp, Cullin, F-box containing complex 
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SET: Su (var), enhancer of zeste, trithorax domain 
TET: human ten-eleven-translocation domain 
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